Industry Groups DxInsights and AdvaMedDx Partner on New Education Initiative

You are here

Industry Groups DxInsights and AdvaMedDx Partner on New Education Initiative

September 28, 2012

BOSTON and WASHINGTON, D.C. – DxInsights, a nonprofit, independent organization devoted to educating stakeholders on the value and power of diagnostics, and AdvaMedDx, a division of the Advanced Medical Technology Association (AdvaMed) representing leading manufacturers of innovative, safe, and effective medical diagnostic tests, today announced that they will be collaborating on a series of short reports that will provide the basics of the most innovative diagnostic technologies.

“Diagnostic tests are ‘smart’ tools that allow medical professionals to understand information from a patient’s body, whether it is a blood glucose test or a DNA test that identifies a cancer patient’s unique genetic markers,” said Andrew Fish, executive director of AdvaMedDx and senior executive vice president of AdvaMed. “Our industry is excited to partner with the team at DxInsights on this initiative that will explain more clearly how advances in diagnostic technology are revolutionizing patient care at every juncture – from diagnosis and prognosis to treatment and follow up care.”

The first report, “Essentials of Diagnostics: Molecular Diagnostics,” is the next installment of DxInsight’s inaugural report, “Essentials of Diagnostics,”  which was introduced in January . Future reports will cover such topics as next generation sequencing, anatomical pathology, and other areas of diagnostic technology relevant to multiple industry stakeholders.

“Molecular diagnostics have exploded over the past 20 years and have revolutionized the diagnosis and monitoring of inherited disease, cancer, infectious disease and numerous other indications,” said Kristin Pothier, founder of DxInsights and partner at Health Advances. “For this reason, we think it’s fitting that the next installment in our ‘Essentials’ series cover this fast-growing and extremely innovative sector of the market, and AdvaMedDx is the perfect partner to collaborate with to bring this valuable educational resource to our health care communities.”

The first report on molecular diagnostics will be released in December of 2012.

For more information, please contact: Ashley McMaster @ (202) 434-7245


AdvaMedDx member companies produce advanced, in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMedDx is the only multi-faceted, policy organization that deals exclusively with issues facing in vitro diagnostic companies both domestically in the United States and abroad. For more information, visit